Rosai-Dorfman-Destombes disease – histiocytic disorder with infl ammatory manifestation

Czech version

Authors: Z. Adam ¹; Z. Adamová ²; L. Pour ¹; Z. Řehák ³; R. Koukalová ³; Z. Král ¹
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Chirurgické oddělení, Vsetínská nemocnice a. s. ²; Oddělení nukleární medicíny, MOU Brno ³
Published in: Klin Onkol 2022; 35(4): 262-170
Category: Review
doi: https://doi.org/10.48095/ccko2022262

Overview

Background: Rosai-Dorfman-Destombes disease (RDD) is a rare histiocytosis characterized by accumulation of activated histiocytes within affected tissues. Although the immunophenotype of this disease was described, the pathophysiology of this disease is still not sufficiently understood. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in RDD lesions, raising the possibility of a clonal origin in some forms of RDD while in other cases reactive origin or association with other malignant and autoimmune disease is supposed. RDD is a widely heterogeneous entity with a range of clinical phenotypes occurring in some patients in association with autoimmune or malignant diseases. Its therapy should reflect the localization of the disease. Monotherapy with glucocorticoids is sufficient only in limited disease. In patients with advanced disease, combined nodal and extranodal forms of RDD need more intensive therapy. In older publications, antimetabolites, vinca alkaloids and prednisone were used; in recent publications, remissions after cladribine, rituximab, sirolimus, thalidomide, lenalidomide and cobimetinib were described. Purpose: This text summarizes current knowledge about this rare disease and reviews the therapeutic options.

Keywords:

sirolimus – lenalidomid – cladribine – rituximab – cyclosporine – Rosai-Dorfman-Destombes disease – cobimetinib

Sources

1. Camprt V. Monitor aneb nemělo by Vám uniknout, že existuje Rosai-Dorfmanova nemoc (i když je poměrně vzácná). [online]. Dostupné z: https: //www.prolekare.cz/casopisy/cesko-slovenska-patologie/2021-3-14/hematopatologie-128074.

2. Kodeová D, Kodet R, Syrůček M et al. Sinus histiocytosis with massive lymphadenopathy – a disseminated form of the Rosai-Dorfman syndrome. Cesk Patol 1996; 32 (2): 53–59.

3. Křenová Z, Bajčiová V, Štěrba J. Histiocytózy u dětí a dospívajících. Onkologie 2016; 10 (5): 206–209.

4. Drlík L, Pock L. Rosai-Dorfmanova nemoc – kožní forma. Čes-slov Derm 2017; 92 (4): 180–183.

5. Mazánek J, Povýšil C. Rosai-Dorfmanova nemoc v oblasti hlavy a krku. Choroby hlavy a krku 2006; 15 (1): 39–43.

6. Destombes P. Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali (4 cases). Bull Soc Pathol Exot Filiales 1965; 58 (6): 1169–1175.

7. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 1969; 87 (1): 63–70.

8. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7 (1): 19–73.

9. Mahzoni P, Zavareh MH, Bagheri M et al. Intracranial Rosai Dorfman disease. J Res Med Sci 2012; 17 (3): 304–307.

10. Paulli M, Bergamaschi G, Tonon L et al. Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol 1995; 91 (2): 415–418. doi: 10.1111/j.1365-2141.1995.tb05313.x.

11. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol 2020; 73 (11): 697–705. doi: 10.1136/jclinpath-2020-206733.

12. Shanmugam V, Margolskee E, Kluk M et al. Rosai-Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol 2016; 10 (3): 394–399. doi: 10.1007/s12105-016-0709-6.

13. Garces S, Medeiros LJ, Patel KP et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 2017; 30 (10): 1367–1377. doi: 10.1038/modpathol.2017.55.

14. Matter MS, Bihl M, Juskevicius D et al. Is Rosai-Dorfman disease a reactive process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. Virchows Arch 2017; 471 (4): 545–547. doi: 10.1007/s00428-017-2173-4.

15. Richardson TE, Wachsmann M, Oliver D et al. BRAF mutation leading to central nervous system rosai-dorfman disease. Ann Neurol 2018; 84 (1): 147–152. doi: 10.1002/ana.25281.

16. Bonometti A, Ferrario G, Parafioriti A et al. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia. J Cutan Pathol 2021; 48 (5): 637–643. doi: 10.1111/cup.13918.

17. Morgan NV, Morris MR, Cangul H et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet 2010; 6 (2): e1000833. doi: 10.1371/journal.pgen.1000833.

18. Xie Y, Pittaluga S, Price S et al. Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation. Haematologica 2017; 102 (2): 364–372. doi: 10.3324/haematol.2015.138081.

19. Maric I, Pittaluga S, Dale JK et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 2005; 29 (7): 903–911. doi: 10.1097/01.pas.0000157997.61177.08.

20. Matson DR, Yang DT. Autoimmune lymphoproliferative syndrome: an overview. Arch Pathol Lab Med 2020; 144 (2): 245–251. doi: 10.5858/arpa.2018-0190-RS.

21. Ragotte RJ, Dhanrajani A, Pleydell-Pearce J et al. A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. Clin Immunol 2017; 175: 143–146. doi: 10.1016/j.clim.2016.12. 006.

22. Lopetegui-Lia N, Asad SD, Jafri SI et al. Autoimmune diseases and Rosai-Dorfman disease coexist more commonly than expected: two case reports. Am J Case Rep 2019; 20: 770–772. doi: 10.12659/AJCR.915627.

23. Meindl A, Rao MS, Yang GY. Extranodal Rosai-Dorfman disease with mucosal involvement of the stomach in a background of autoimmune atrophic gastritis. Int J Surg Pathol 2018; 26 (7): 671–675. doi: 10.1177/ 1066896918773399.

24. Ambati S, Chamyan G, Restrepo R et al. Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 51 (3): 433–435. doi: 10.1002/pbc.21 606.

25. Hassani J, Porubsky C, Berman C et al. Intraperitoneal Rosai-Dorfman disease associated with clear cell sarcoma: first case report. Pathology 2016; 48 (7): 742–744. doi: 10.1016/j.pathol.2016.07.015.

26. Garces S, Yin CC, Patel KP et al. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol 2019; 32 (1): 16–26. doi: 10.1038/s41379-018-0152-1.

27. Garg KK, Singh H. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) and anaplastic large cell lymphoma. Eur J Case Rep Intern Med 2017; 4 (5): 000605. doi: 10.12890/2017_000605.

28. Bezerra Lima L, Alves Sobreira-Neto M, Braga-Neto P et al. Isolated central nervous system Rosai-Dorfman disease and breast cancer: an unusual presentation. Int J Neurosci 2019; 129 (4): 393–396. doi: 10.1080/ 00207454.2018.1533823.

29. Menon MP, Evbuomwan MO, Rosai J et al. A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease? Histopathology 2014; 64 (3): 455–459. doi: 10.1111/his.12274.

30. Liu L, Perry AM, Cao W et al. Relationship between Rosai-Dorfman disease and IgG4-related disease: study of 32 cases. Am J Clin Pathol 2013; 140 (3): 395–402. doi: 10.1309/AJCPFH0SJ6YILXJU.

31. Emile JF, Vaglio A, Cohen-Aubart F et al. IgG4-related disease and Rosai-Dorfman-Destombes disease – authors‘ reply. Lancet 2021; 398 (10307): 1214–1215. doi: 10.1016/S0140-6736 (21) 01811-0.

32. Hasegawa M, Sakai F, Okabayashi A et al. Rosai-Dorfman disease of the lung overlapping with IgG4-related disease: the difficulty in is differential diagnosis. Intern Med 2017; 56 (8): 937–941. doi: 10.2169/internalmedicine.56.7609.

33. Hoffmann JC, Lin CY, Bhattacharyya S et al. Rosai-Dorfman disease of the breast with variable IgG4+ plasma cells: a diagnostic mimicker of other malignant and reactive entities. Am J Surg Pathol 2019; 43 (12): 1653–1660. doi: 10.1097/PAS.0000000000001347.

34. Iyengar NS, Golub D, McQuinn MW et al. Orbital Rosai-Dorfman disease initially diagnosed as IgG4-related disease: a case report. Acta Neuropathol Commun 2020; 8 (1): 113. doi: 10.1186/s40478-020-00995-6.

35. Kurahashi S, Toda N, Fujita M et al. Acute tubulointerstitial nephritis in Rosai-Dorfman disease mimicking IgG4-related disease. Intern Med 2022; 61 (7): 1027–1032. doi: 10.2169/internalmedicine.8046-21.